Clinical efficacy and safety of Securflux®, an anti-reflux device for intravenous infusion
Clinical efficacy and safety of Securflux®, an anti-reflux device for intravenous infusion
J Vasc Access 2013; 14(1): 77 - 82
DOI:10.5301/jva.5000095
Authors
Ferran Barreras, Manuel Cabeza, Laura Collantes de Terán
Abstract
Purpose: Catheter obstruction or patency inhibition of the venous access cannula is a frequently experienced problem in patients to whom intravenous (IV) solutions are administered. In this study we assessed the efficacy and safety of Securflux® a disposable device with a back-check valve to prevent reflux in IV infusion sets. Methods: A total of 177 adult patients requiring IV medication for at least 24 hours duration were randomized into two groups: with and without the use of Securflux®. Assessments were performed the 10 days after catheter insertion, over three daily visits. The incidence of the onset of reflux (visual/non-visual) and the consequences of reflux for both the patient and healthcare staff were assessed. Results: There were 4577 follow-up (study) visits (53.4% in patients with Securflux® and 46.6% without Securflux®). Venous reflux was observed in 14.2% of all visits, more frequently without Securflux® (21.3% vs. 8.1%; P<.05). Reflux was mostly visual without Securflux® (7.6% vs. 0.7%) and non-visual with Securflux® (13.6% vs. 7.3%). The onset of venous reflux carried more consequences, such as inhibition of the line and patient discomfort, in the infusions without Securflux® (81.1% vs. 73.5% of the visits; P<.05). There were no safety concerns related to Securflux®. Conclusions: Securflux® is effective, safe and useful for the prevention of venous reflux onset in patients administered IV medication.
Article History
- • Accepted on 02/07/2012
- • Available online on 03/08/2012
- • Published in print on 05/04/2013
Article usage statistics
The blue line displays unique views in the time frame indicated.
The yellow line displays unique downloads.
Views and downloads are counted only once per session.
Authors
-
Barreras, Ferran [PubMed] [Google Scholar]
Department of Clinical Hematology, Hospital de la Santa Creu i Sant Pau, Barcelona - Spain
-
Cabeza, Manuel [PubMed] [Google Scholar]
Post-Acute Care Unit, Hospital de la Santa Creu i Sant Pau, Barcelona - Spain
-
Collantes de Terán, Laura [PubMed] [Google Scholar]
Department of Pharmacovigilance and Scientific Support, Laboratorios Grifols S.A., Parets del Vallès, Barcelona - Spain